Drug intelligence / Profile preview

SXRN

Development stage: Phase 1
Lead developer: Jiangsu Nutai Biologics
Modality: Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

SXRN is a naked plasmid DNA drug developed by Jiangsu Nutai Biologics Co., Ltd. It functions as an RNA therapy by targeting miRNA-214, which subsequently ameliorates cancer cachexia-associated metabolic disorders through the regulation of the Adenosine A2A Receptor (A2AR). Preclinical studies have demonstrated its efficacy in animal models, showing benefits such as weight maintenance, prolonged survival, and suppression of tumor growth. SXRN is currently undergoing Phase I clinical trials for advanced solid tumors and cancer cachexia.

Other names: SXRN Plasmid DNA TechniqueSXRN Injection

Beyond the preview

Go deeper on SXRN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SXRN.

Explore the full profile